Browsing by Author "Korać, Miloš (10040016700)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication A pilot study in Serbia by European clostridium difficile infection surveillance network(2020) ;Jovanović, Milica (56765272500) ;van Dorp, Sofie M. (56549896100) ;Drakulović, Mitra (6507165169) ;Papić, Dubravka (57216824235) ;Pavić, Sladjana (6603595864) ;Jovanović, Snežana (7102384849) ;Lešić, Aleksandar (55409413400) ;Korać, Miloš (10040016700) ;Milošević, Ivana (58456808200)Kuijper, Ed J. (24429752400)Clostridium (Clostridioides) difficile infections (CDIs) are among the most frequent healthcare-associated infections in Serbia. In 2013, Serbia participated in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) who launched a pilot study to enhance laboratory capacity and standardize surveillance for CDI. Two clinics of Clinical Center of Serbia [Clinic for Infectious and Tropical Diseases (CITD) and Clinic of Orthopedic Surgery and Traumatology (COT)] from Belgrade and one general hospital from another metropolitan area of Serbia, Užice, participated. During a period of 3 months in 2013, all patients with diagnosed CDI were included. The CDI incidence rates in CITD, COT, and General Hospital Užice were 19.0, 12.2, and 3.9 per 10,000 patient-days, respectively. In total, 49 patients were enrolled in the study with average age of 72 years. A complicated course of CDI was found in 14.3% of all patients. Six (12.2%) of 49 patients died, but not attributable to CDI. Of 39 C. difficile isolates, available for ribotyping, 78.9% belonged to ribotype 027; other PCR ribotypes were 001, 015, 002, 005, 010, 014, and 276. Antimicrobial susceptibility testing revealed low levels of MIC50 and MIC90 for metronidazole (0.5 μg/ml both) and vancomycin (0.25 and 0.5 μg/ml), while 28 strains of ribotype 027 were resistant to moxifloxacin with MIC ≥4 μg/ml. National surveillance is important to obtain more insight in the epidemiology of CDI and to compare the results with other European countries. This study by ECDIS-Net gives bases for a national surveillance of CDI in Serbia. © 2019 Akadémiai Kiadó, Budapest. - Some of the metrics are blocked by yourconsent settings
Publication A pilot study in Serbia by European clostridium difficile infection surveillance network(2020) ;Jovanović, Milica (56765272500) ;van Dorp, Sofie M. (56549896100) ;Drakulović, Mitra (6507165169) ;Papić, Dubravka (57216824235) ;Pavić, Sladjana (6603595864) ;Jovanović, Snežana (7102384849) ;Lešić, Aleksandar (55409413400) ;Korać, Miloš (10040016700) ;Milošević, Ivana (58456808200)Kuijper, Ed J. (24429752400)Clostridium (Clostridioides) difficile infections (CDIs) are among the most frequent healthcare-associated infections in Serbia. In 2013, Serbia participated in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) who launched a pilot study to enhance laboratory capacity and standardize surveillance for CDI. Two clinics of Clinical Center of Serbia [Clinic for Infectious and Tropical Diseases (CITD) and Clinic of Orthopedic Surgery and Traumatology (COT)] from Belgrade and one general hospital from another metropolitan area of Serbia, Užice, participated. During a period of 3 months in 2013, all patients with diagnosed CDI were included. The CDI incidence rates in CITD, COT, and General Hospital Užice were 19.0, 12.2, and 3.9 per 10,000 patient-days, respectively. In total, 49 patients were enrolled in the study with average age of 72 years. A complicated course of CDI was found in 14.3% of all patients. Six (12.2%) of 49 patients died, but not attributable to CDI. Of 39 C. difficile isolates, available for ribotyping, 78.9% belonged to ribotype 027; other PCR ribotypes were 001, 015, 002, 005, 010, 014, and 276. Antimicrobial susceptibility testing revealed low levels of MIC50 and MIC90 for metronidazole (0.5 μg/ml both) and vancomycin (0.25 and 0.5 μg/ml), while 28 strains of ribotype 027 were resistant to moxifloxacin with MIC ≥4 μg/ml. National surveillance is important to obtain more insight in the epidemiology of CDI and to compare the results with other European countries. This study by ECDIS-Net gives bases for a national surveillance of CDI in Serbia. © 2019 Akadémiai Kiadó, Budapest. - Some of the metrics are blocked by yourconsent settings
Publication A rare case of Candida parapsilosis endocarditis in a young healthy woman - case report(2013) ;Pelemiš, Mijomir (6507978433) ;Stevanović, Goran (15059280200) ;Lavadinović, Lidija (22941135800) ;Matić, Snežana (37049011100) ;Milošević, Ivana (58456808200) ;Korać, Miloš (10040016700) ;Pelemiš, Svetislav (55251583000) ;Nedeljković, Milan (7004488186)Prostran, Milica (7004009031)Disseminated fungal infections are still rare conditions, mostly caused by Candida spp. during immunosuppression. Infection of immunocompetent individuals is uncommon. Endocarditis is a rare manifestation during candidaemia, mostly in patients with prosthetic valves. Affection of previously unaltered valves is uncommon. We presented a case of a young, previously healthy female patient with endocarditis, caused by Candida parapsilosis. The initial symptom, fever, was present four months before hospital admittance. She was febrile without other symptoms and during observation in a local hospital. After her condition deteriorated, she was transferred to the Institute for infectious and tropical diseases, Belgrade. Clinical findings on admission include petechial skin rash and moderate hepatosplenomegaly. Newly developed systolic murmur was noted, and Candida parapsilosis was isolated in multiple blood cultures. Echocardiography revealed 15 × 14 mm vegetations on the right aortic vellum. She was treated with antifungal drugs (fluconasole, liposomal amphotericin B), and the affected valve was successfully replaced. The same strain of Candida parapsilosis was isolated from the intraoperative material of the valve. There were no markers of immunosuppression or other conditions which could affect the immune system. After a prolonged period of treatment she was successfully cured, and she received a long-term intermittent suppressive fluconasole therapy for the time being. © 2013 Pelemiš et al; licensee BioMed Central Ltd. - Some of the metrics are blocked by yourconsent settings
Publication FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - A developing country’s perspective in DAA era(2018) ;Karić, Uroš (57201195591) ;Pešić-Pavlović, Ivana (36473869000) ;Stevanović, Goran (15059280200) ;Korać, Miloš (10040016700) ;Nikolić, Nataša (58288723700) ;Radovanović-Spurnić, Aleksandra (57191847101) ;Barać, Aleksandra (55550748700) ;Mitrović, Nikola (55110096400) ;Marković, Aleksandar (57198206234) ;Marković, Marko (57534497700) ;Petković, Anita (57201547687) ;Ostojić, Ivana (56005428100) ;Peruničić, Sanja (57191926042) ;Kekić, Natalija (57201548083) ;Glidžić, Martina (57201551635) ;Đonin-Nenezić, Miljana (57201195027) ;Brmbolić, Branko (6701712863)Milošević, Ivana (58456808200)Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis. Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage. Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort. Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible. © 2018 Karić et al. - Some of the metrics are blocked by yourconsent settings
Publication FIB-4 and APRI scores for predicting severe fibrosis in chronic hepatitis C - A developing country’s perspective in DAA era(2018) ;Karić, Uroš (57201195591) ;Pešić-Pavlović, Ivana (36473869000) ;Stevanović, Goran (15059280200) ;Korać, Miloš (10040016700) ;Nikolić, Nataša (58288723700) ;Radovanović-Spurnić, Aleksandra (57191847101) ;Barać, Aleksandra (55550748700) ;Mitrović, Nikola (55110096400) ;Marković, Aleksandar (57198206234) ;Marković, Marko (57534497700) ;Petković, Anita (57201547687) ;Ostojić, Ivana (59954448700) ;Peruničić, Sanja (57191926042) ;Kekić, Natalija (57201548083) ;Glidžić, Martina (57201551635) ;Đonin-Nenezić, Miljana (57201195027) ;Brmbolić, Branko (6701712863)Milošević, Ivana (58456808200)Introduction: Chronic Hepatitis C Virus (HCV) infection leads to progressive fibrosis making fibrosis staging necessary in the evaluation of such patients. Different fibrosis scores are emerging as possible non-invasive alternatives for liver biopsy. The Fibrosis-4 Index (FIB-4) and AST to Platelet Ratio Index (APRI) scores are the most widely used and the most extensively tested. This study aims to determine if it was possible to accurately use these to identify patients that are unlikely to have severe fibrosis. Methodology: One hundred and forty-two patients with chronic hepatitis C infection who underwent liver biopsy since January 1st 2014 until May 31st 2017 at the Hospital for Infectious and Tropical Diseases in Belgrade were analyzed. The FIB-4 and APRI scores were calculated for each patient and compared to histologically determined fibrosis stage. Results: A comprehensive statistical analysis was conducted in order to compare patients with and without severe fibrosis and to evaluate the accuracy of the fibrosis scores. Patients with non-severe fibrosis were younger, had higher platelet counts and lower transaminase levels. FIB-4 had an AUC of 0.875 and the APRI score had an AUC of 0.861. No patients with severe fibrosis or cirrhosis had a FIB-4 lower than 1.08. FIB-4 was superior to APRI in identifying patients with severe fibrosis in the study cohort. Conclusion: FIB-4 was superior to APRI in the recognition of severe fibrosis. FIB-4 may prove very useful in identifying patients without advanced liver disease, especially if other non-invasive methods are inaccessible. © 2018 Karić et al. - Some of the metrics are blocked by yourconsent settings
Publication Taeniosis and cysticercosis in Serbia, 1990–2018: Significance of standard of living(2019) ;Stopić, Milena (57210965993) ;Bobić, Branko (6602175788) ;Dakić, Zorica (35186070500) ;Srbljanović, Jelena (56829608600) ;Štajner, Tijana (57260071000) ;Konstantinović, Neda (57218579455) ;Srećković, Katarina (57210965559) ;Klun, I. (55919253000) ;Korać, Miloš (10040016700)Djurković-Djaković, Olgica (6701811845)Objectives: As is the case for all of Southeast Europe, Serbia is an area traditionally endemic for Taenia saginata and Taenia solium infections. This study was performed to analyse the epidemiological data on taeniosis and cysticercosis in Serbia for the period 1990–2018. Methods: Data on cases of T. saginata and T. solium infection were collected via a systematic search of published articles, the grey literature, and official reports, as well as by performing clinical observational studies of patients treated in the departments for infectious diseases of hospitals and university clinics in Serbia. Results: A total of 212 cases of taeniosis were reported, all between 1997 and 2004 when taeniosis was notifiable (incidence range 0.04–0.9/100 000 population/year). From 1990 to 2018, 170 cases of cysticercosis (all but one of neurocysticercosis), were registered (incidence range 0–0.29/100 000 population/year), with a strong decrease since 2000 and a single case in the last 9 years. The annual number of cases of both taeniosis (Pearson's r = 0.914, p = 0.001) and cysticercosis (Pearson's r = 0.582, p = 0.014) correlated with the consumer price index. Conclusions: In Serbia, T. saginata and T. solium infections are autochthonous but occur only sporadically. However, the potential for re-emergence exists, depending on the socio-economic state of the country. © 2019 The Author(s)
